A Study to Evaluate Chronic Hepatitis C Infection in Adult Liver Transplant Recipients
Study for adult liver transplant recipients with chronic Hepatitis C infection using study drug (ABT-450/r/ABT-267)
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAL1758
U.S. Govt. ID: NCT01782495
Contact: Theresa Lukose: 212-305-3839 / tt2103@columbia.edu
Additional Study Information: The purpose of this study is to see if study drugs ABT-450/r/ABT-267, and ABT-333 taken with RBV are safe and able to reduce the amount of Hepatitis C Virus (HCV) in subjects' blood over a 24-week treatment period. These drugs are intended to prevent the HCV from multiplying in the human body. Subjects who participate in this study will be expected to undergo various activities, tests and evaluations over the course of 24 weeks.
This study is closed
Investigator
Robert Brown, MD, MPH
Do You Qualify?
Have you had a recent liver transplant? Yes No
Do you have a history of any post-transplant complications? Yes No
Are you taking immunosuppressants? Yes No
Have you had a HCV infection? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Theresa Lukose
tt2103@columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE